Decrease of Neuropsychiatric Side Effects After Switching From Atripla to Eviplera
Status:
Terminated
Trial end date:
2016-12-21
Target enrollment:
Participant gender:
Summary
The aim of this prospective, open label study is to check for differences in neuropsychiatric
and neurocognitive measurements among patients that will be switched from Atripla to Eviplera
among 40 patients.
Phase:
Phase 4
Details
Lead Sponsor:
Sheba Medical Center
Treatments:
Efavirenz Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Emtricitabine Emtricitabine, Rilpivirine, Tenofovir Drug Combination Rilpivirine Tenofovir